1.82
Schlusskurs vom Vortag:
$1.74
Offen:
$1.74
24-Stunden-Volumen:
30,159
Relative Volume:
0.01
Marktkapitalisierung:
$3.86M
Einnahmen:
$212.10K
Nettoeinkommen (Verlust:
$-40.19M
KGV:
-0.000343
EPS:
-5313.2836
Netto-Cashflow:
$-13.92M
1W Leistung:
+13.04%
1M Leistung:
-21.21%
6M Leistung:
-97.85%
1J Leistung:
-99.99%
Aditxt Inc Stock (ADTX) Company Profile
Firmenname
Aditxt Inc
Sektor
Branche
Telefon
909-488-0844
Adresse
737 N. FIFTH STREET, SUITE 200, RICHMOND
Vergleichen Sie ADTX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ADTX
Aditxt Inc
|
1.82 | 1.94M | 212.10K | -40.19M | -13.92M | -5,313.28 |
![]()
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Aditxt Inc Aktie (ADTX) Neueste Nachrichten
Aditxt (ADTX) Cancels Acquisition Agreement with Appili Therapeu - GuruFocus
Aditxt Discusses Strategic Focus and Growth Plans - TipRanks
Aditxt to Scrap Merger Deal With Appili Therapeutics - marketscreener.com
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics | ADTX Stock News - GuruFocus
Aditxt Announces Termination Of Arrangement Agreement With Appili Therapeutics - marketscreener.com
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. - The Manila Times
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics - Business Wire
Aditxt, Inc. SEC 10-Q Report - TradingView
Aditxt Highlights Progress of ADI-100TM in Autoimmune Treatment - TipRanks
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Quantisnow
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, - GuruFocus
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department - GuruFocus
Aditxt secures $256K through senior note sales By Investing.com - Investing.com Nigeria
Aditxt secures $256K through senior note sales - Investing.com
Aditxt’s Subsidiary Pearsanta Gets IRB Approval - TipRanks
Aditxt Delivers Shareholder Update and 2024 Year-End Plan - ADVFN
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™ - Quantisnow
Pre-market Movers: RGC, SYRS, ADTX, ATXI... - RTTNews
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adim - GuruFocus
Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™ - Business Wire
Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune - Bluefield Daily Telegraph
Aditx Therapeutics Stock Hits 52-Week Low at $2.35 By Investing.com - Investing.com South Africa
Aditx Therapeutics Stock Hits 52-Week Low at $2.35 - Investing.com Australia
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 | ADTX Stock News - GuruFocus
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 - Business Wire
Aditxt (ADTX) Study Reinforces ADI-100's Promise in Autoimmune T - GuruFocus
Aditxt Subsidiary Adimune Announces Positive Results from Mayo C - GuruFocus
Aditxt Regains Nasdaq Compliance with Bid Price - TipRanks
Aditxt announces results from ADI-100 study - TipRanks
Aditxt Subsidiary Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies To Support FDA And European Regulatory Submissions For Type 1 Diabetes, Psoriasis, And Stiff Person Syndrome Human Trials - marketscreener.com
Aditxt (ADTX) Study Reinforces ADI-100's Promise in Autoimmune Treatments | ADTX Stock News - GuruFocus
Evofem Biosciences to Present at Emerging Growth Conference - Quantisnow
Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Business Wire
Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements | ADTX Stock News - GuruFocus
ADITXT Earnings Preview: Recent $ADTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Aditxt regains Nasdaq compliance, updates on operations By Investing.com - Investing.com India
Aditxt Weekly Update to Highlight Recent Events, Including Regai - GuruFocus
Aditxt regains Nasdaq compliance, updates on operations - Investing.com
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements - Business Wire
Why Aditxt Inc. (ADTX) Went Down On Thursday? - Insider Monkey
Aditxt invests $1.5 million in Evofem amid merger talks By Investing.com - Investing.com Australia
Finanzdaten der Aditxt Inc-Aktie (ADTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):